Sanctuary Advisors LLC Acquires New Holdings in Krystal Biotech, Inc. $KRYS

Sanctuary Advisors LLC bought a new position in Krystal Biotech, Inc. (NASDAQ:KRYS) in the second quarter, HoldingsChannel.com reports. The fund bought 2,692 shares of the company’s stock, valued at approximately $1,001,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Handelsbanken Fonder AB boosted its position in Krystal Biotech by 58.4% in the fourth quarter. Handelsbanken Fonder AB now owns 105,800 shares of the company’s stock worth $26,084,000 after purchasing an additional 39,000 shares during the last quarter. Fisher Asset Management LLC bought a new position in shares of Krystal Biotech in the 4th quarter worth approximately $933,000. Principal Financial Group Inc. lifted its stake in shares of Krystal Biotech by 15.6% in the 4th quarter. Principal Financial Group Inc. now owns 165,074 shares of the company’s stock worth $40,697,000 after purchasing an additional 22,231 shares during the period. Biondo Investment Advisors LLC boosted its holdings in shares of Krystal Biotech by 31.3% in the fourth quarter. Biondo Investment Advisors LLC now owns 68,130 shares of the company’s stock worth $16,797,000 after buying an additional 16,245 shares during the last quarter. Finally, William Blair Investment Management LLC grew its position in Krystal Biotech by 152.1% during the fourth quarter. William Blair Investment Management LLC now owns 376,340 shares of the company’s stock valued at $92,783,000 after buying an additional 227,038 shares during the period. 86.29% of the stock is owned by institutional investors.

Krystal Biotech Stock Performance

KRYS stock opened at $357.46 on Friday. The company’s fifty day moving average price is $348.57 and its 200-day moving average price is $303.83. Krystal Biotech, Inc. has a one year low of $136.73 and a one year high of $382.54. The company has a market capitalization of $10.58 billion, a PE ratio of 44.79 and a beta of 0.53.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, August 3rd. The company reported $1.79 earnings per share for the quarter, beating the consensus estimate of $1.70 by $0.09. The company had revenue of $119.22 million during the quarter, compared to analysts’ expectations of $120.93 million. Krystal Biotech had a net margin of 54.82% and a return on equity of 19.34%. On average, research analysts predict that Krystal Biotech, Inc. will post 7.68 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. Evercore reiterated an “outperform” rating and set a $300.00 price target on shares of Krystal Biotech in a research note on Tuesday, May 5th. Citigroup raised their target price on Krystal Biotech from $378.00 to $386.00 and gave the stock a “buy” rating in a report on Tuesday, August 4th. Royal Bank Of Canada began coverage on Krystal Biotech in a research report on Friday, August 14th. They set an “outperform” rating and a $400.00 target price on the stock. TD Cowen upped their price target on Krystal Biotech from $306.00 to $403.00 and gave the stock a “buy” rating in a research report on Thursday, June 18th. Finally, HC Wainwright raised their price objective on Krystal Biotech from $310.00 to $361.00 and gave the stock a “buy” rating in a research note on Tuesday, June 16th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Krystal Biotech has an average rating of “Moderate Buy” and an average target price of $365.40.

Insider Activity

In other news, EVP John Charles Thomas sold 1,000 shares of Krystal Biotech stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $347.27, for a total value of $347,270.00. Following the sale, the executive vice president directly owned 1,000 shares of the company’s stock, valued at approximately $347,270. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Dino A. Rossi sold 25,000 shares of the business’s stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $329.12, for a total value of $8,228,000.00. Following the completion of the sale, the director owned 50,000 shares in the company, valued at $16,456,000. This represents a 33.33% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 51,000 shares of company stock worth $16,278,020 over the last 90 days. Corporate insiders own 13.10% of the company’s stock.

Krystal Biotech Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.